NCT02504463View on ClinicalTrials.gov

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
DRUG

Samidorphan IV

Single IV administration

DRUG

[14c]-Samidorphan sublingual

Single sublingual administration containing radiolabel

DRUG

[14c]-Samidorphan oral

Single oral administration containing radiolabel

Trial Locations (1)

78744

Alkermes Investigational Site, Austin

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY